Details

Autor(en) / Beteiligte

• Levink, Iris J M
• Jaarsma, Sanne C
• Koopmann, Brechtje D M
• van Riet, Priscilla A
• Overbeek, Kasper A
• Meziani, Jihane
• Sprij, Marloes L J A
• Casadei, Riccardo
• Ingaldi, Carlo
• Polkowski, Marcin
• Engels, Megan M L
• van der Waaij, Laurens A
• Carrara, Silvia
• Pando, Elizabeth
• Vornhülz, Marlies
• Honkoop, Pieter
• Schoon, Erik J
• Laukkarinen, Johanna
• Bergmann, Jilling F
• Rossi, Gemma
• van Vilsteren, Frederike G I
• van Berkel, Anne-Marie
• Tabone, Trevor
• Schwartz, Matthijs P
• Tan, Adriaan C I T L
• van Hooft, Jeanin E
• Quispel, Rutger
• van Soest, Ellert
• Czacko, Laszlo
• Bruno, Marco J
• Cahen, Djuna L

Titel

The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program

Ist Teil von

• United European gastroenterology journal, 2023-09, Vol.11 (7), p.601-611

Ort / Verlag

England: John Wiley & Sons, Inc

Erscheinungsjahr

2023

Quelle

Wiley Blackwell Single Titles

Beschreibungen/Notizen

• Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate the role of CA19.9 monitoring for early detection and management in a cyst surveillance population. The PACYFIC-registry is a prospective collaboration that investigates the yield of pancreatic cyst surveillance performed at the discretion of the treating physician. We included participants for whom at least one serum CA19.9 value was determined by a minimum follow-up of 12 months. Of 1865 PACYFIC participants, 685 met the inclusion criteria for this study (mean age 67 years, SD 10; 61% female). During a median follow-up of 25 months (IQR 24, 1966 visits), 29 participants developed high-grade dysplasia (HGD) or pancreatic cancer. At baseline, CA19.9 ranged from 1 to 591 kU/L (median 10 kU/L [IQR 14]), and was elevated (≥37 kU/L) in 64 participants (9%). During 191 of 1966 visits (10%), an elevated CA19.9 was detected, and these visits more often led to an intensified follow-up (42%) than those without an elevated CA19.9 (27%; p < 0.001). An elevated CA19.9 was the sole reason for surgery in five participants with benign disease (10%). The baseline CA19.9 value was (as continuous or dichotomous variable at the 37 kU/L threshold) not independently associated with HGD or pancreatic cancer development, whilst a CA19.9 of ≥ 133 kU/L was (HR 3.8, 95% CI 1.1-13, p = 0.03). In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false-positive values. The role of CA19.9 monitoring should be critically appraised prior to implementation in surveillance programs and guidelines.